TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD

QQQ $ 625.32 $ 0.00 (0 %)

DIA $ 480.57 $ 0.00 (0 %)

SPY $ 685.36 $ 0.00 (0 %)

TLT $ 89.90 $ 0.00 (0 %)

GLD $ 379.56 $ 0.00 (0 %)

Previous Close

$ 25.13

Open

$ 24.29

Bid

$ 25.17 x 2,000

Ask

$ 25.25 x 1

Day's Range

-- - --

52 Week Range

$ 12.47 - $ 25.35

Volume

15,259,902

Average Volume

Market Cap

28.83B

Beta (5Y Monthly)

$ 0.88

PE Ratio (TTM)

$ 40.49

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	07-30-2025	06-30-2025	10-Q
3	05-07-2025	03-31-2025	10-Q
4	02-05-2025	12-31-2024	10-K
5	11-06-2024	09-30-2024	10-Q
6	07-31-2024	06-30-2024	10-Q
7	05-08-2024	03-31-2024	10-Q
8	02-12-2024	12-31-2023	10-K
9	11-09-2023	09-30-2023	10-Q
10	08-02-2023	06-30-2023	10-Q
11	05-10-2023	03-31-2023	10-Q
12	02-10-2023	12-31-2022	10-K
13	11-03-2022	09-30-2022	10-Q
14	07-27-2022	06-30-2022	10-Q
15	05-03-2022	03-31-2022	10-Q
16	02-09-2022	12-31-2021	10-K
17	10-27-2021	09-30-2021	10-Q
18	07-28-2021	06-30-2021	10-Q
19	04-28-2021	03-31-2021	10-Q
20	02-10-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-05-2020	06-30-2020	10-Q
23	05-07-2020	03-31-2020	10-Q
24	02-21-2020	12-31-2019	10-K
25	11-07-2019	09-30-2019	10-Q
26	08-07-2019	06-30-2019	10-Q
27	05-02-2019	03-31-2019	10-Q
28	02-19-2019	12-31-2018	10-K
29	11-01-2018	09-30-2018	10-Q
30	08-02-2018	06-30-2018	10-Q
31	05-03-2018	03-31-2018	10-Q
32	02-12-2018	12-31-2017	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
11/11/2025 17:35:21

Here's How Much $100 Invested In Teva Phar...
11/10/2025 23:00:31

Price Over Earnings Overview: Teva Pharmac...
11/10/2025 18:00:38

expedia-sandisk-and-penumbra-are-among-the-top-10-large-cap-gainers-last-week-nov-3-nov-7-are-the-others-in-your-portfolio

Expedia, Sandisk and Penumbra Are Among th...
11/09/2025 12:08:44

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad do...

Teva Pharmaceuticals Industries Presents N...
11/07/2025 23:04:45

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presen...

JP Morgan Maintains Overweight on Teva Pha...
11/06/2025 22:05:14

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

Teva Canada Says Welcomes Health Canada An...
11/06/2025 13:08:40

10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

johnson-controls-babcock--wilcox-lemonade-lumentum-teva-pharmaceutical-and-other-big-stocks-moving-higher-on-wednesday

Johnson Controls, Babcock & Wilcox, Lemona...
11/05/2025 16:56:53

teva-pharmas-key-branded-drugs-fuel-strong-revenue-growth-lifts-full-year-profit-outlook

Teva Pharma's Key Branded Drugs Fuel Stron...
11/05/2025 16:30:13

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65.

Teva Pharm CEO Francis Tells Reuters Co. W...
11/05/2025 15:06:54

-Reuters

Teva Pharmaceutical Indus Raises FY2025 Ad...
11/05/2025 12:06:17

Teva Pharmaceutical Indus (NYSE:TEVA) raises FY2025 Adj EPS guidance from $2.50-$2.60 to $2.55-$2.65 vs $2.58 analyst estimate....

Teva Pharmaceutical Indus Q3 Adj. EPS $0.7...
11/05/2025 12:04:51

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate ...

Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

Teva Pharmaceutical's Unit Enters License ...
10/20/2025 20:31:32

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:AND) entered into a license ...

scisparc-expands-biotech-ambitions-buys-stake-in-miza-iii-ventures

SciSparc Expands Biotech Ambitions, Buys S...
10/15/2025 13:34:30

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza ...

Teva Pharmaceuticals Announces FDA Approve...
10/10/2025 19:01:29

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive t...

teva-viatris-on-investor-watch-as-white-house-spares-generic-drugs-from-tariffs

Teva, Viatris On Investor Watch As White H...
10/09/2025 13:31:09

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...

SciSparc And AutoMax Call Off Merger
10/06/2025 12:55:03

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

JP Morgan Maintains Overweight on Teva Pha...
10/03/2025 12:21:58

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...